Last reviewed · How we verify
1% Lidocaine
At a glance
| Generic name | 1% Lidocaine |
|---|---|
| Also known as | Lidoderm, Xylocaine, Recticare, Anecream,, Solarcaine, Anestacon, Cutiecaine, Lidocoll,, A, LIDOCAINE |
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Closed Versus Open Lateral Internal Sphincterotomy for Chronic Anal Fissure (NA)
- OMT for Adhesive Capsulitis (PHASE4)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Jaw Muscle Pain Post Wisdom Molar Surgery (PHASE2)
- Comparison of the Effectiveness of Exercise, Dry Needling and Interfascial Block Treatments in the Treatment of Myofascial Pain Syndrome (NA)
- Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1% Lidocaine CI brief — competitive landscape report
- 1% Lidocaine updates RSS · CI watch RSS
- Duke University portfolio CI